MY117582A - Oxacarbazepine film-coated tablets - Google Patents

Oxacarbazepine film-coated tablets

Info

Publication number
MY117582A
MY117582A MYPI98000504A MYPI9800504A MY117582A MY 117582 A MY117582 A MY 117582A MY PI98000504 A MYPI98000504 A MY PI98000504A MY PI9800504 A MYPI9800504 A MY PI9800504A MY 117582 A MY117582 A MY 117582A
Authority
MY
Malaysia
Prior art keywords
coated tablets
film
oxacarbazepine
formulations
oxacarbazepine film
Prior art date
Application number
MYPI98000504A
Other languages
English (en)
Inventor
Burkhard Dr Schlutermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4184588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY117582(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY117582A publication Critical patent/MY117582A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MYPI98000504A 1997-02-14 1998-02-09 Oxacarbazepine film-coated tablets MY117582A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH33197 1997-02-14

Publications (1)

Publication Number Publication Date
MY117582A true MY117582A (en) 2004-07-31

Family

ID=4184588

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98000504A MY117582A (en) 1997-02-14 1998-02-09 Oxacarbazepine film-coated tablets

Country Status (31)

Country Link
US (2) US20070036863A1 (https=)
EP (1) EP0966287B1 (https=)
JP (3) JP2000511935A (https=)
KR (3) KR19980071337A (https=)
CN (2) CN1626093A (https=)
AR (1) AR011142A1 (https=)
AT (1) ATE239481T1 (https=)
AU (1) AU738030B2 (https=)
BR (1) BR9807368A (https=)
CA (1) CA2277791C (https=)
CO (1) CO4920215A1 (https=)
CY (1) CY2480B1 (https=)
CZ (1) CZ298840B6 (https=)
DE (1) DE69814367T2 (https=)
DK (1) DK0966287T3 (https=)
ES (1) ES2199422T3 (https=)
HU (1) HU227807B1 (https=)
ID (1) ID22348A (https=)
MY (1) MY117582A (https=)
NO (1) NO327486B1 (https=)
NZ (1) NZ336946A (https=)
PE (1) PE58999A1 (https=)
PL (1) PL193332B1 (https=)
PT (1) PT966287E (https=)
RU (1) RU2201218C2 (https=)
SK (1) SK284503B6 (https=)
TR (1) TR199901804T2 (https=)
TW (1) TW529957B (https=)
UY (1) UY24888A1 (https=)
WO (1) WO1998035681A1 (https=)
ZA (1) ZA981205B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
PL371259A1 (pl) 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
EP1663247B1 (en) 2003-09-03 2009-10-28 Novartis AG Use of oxcarbazepine for the improvement of sleep in patients suffering from chronic pain
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
DE602006011485D1 (de) 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
WO2007053904A1 (en) * 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
JP2008540346A (ja) * 2006-01-31 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド オキシカルバゼピンの医薬製剤及びその調製方法
EP1815849A1 (en) * 2006-01-31 2007-08-08 Teva Pharmaceutical Industries Ltd Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2010499A4 (en) * 2006-04-21 2012-07-18 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION OF OXCARBAZEPINE PARTICULATE FROM 15 TO 30 MICRONS IN AVERAGE
ES2360423T3 (es) * 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
EP2476418A1 (en) 2006-12-21 2012-07-18 Alphapharm Pty Ltd. Pharmaceutical compound and composition for use in treating type II diabetes comprising rosiglitazone in a specific particle size
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
WO2008141751A2 (en) * 2007-05-23 2008-11-27 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103735527B (zh) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
TWI853027B (zh) 2019-05-16 2024-08-21 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (ja) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd コ−テイング剤組成物
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
CA2277791A1 (en) 1998-08-20
DE69814367T2 (de) 2004-02-26
KR20120079826A (ko) 2012-07-13
AR011142A1 (es) 2000-08-02
KR19980071337A (ko) 1998-10-26
DK0966287T3 (da) 2003-08-25
AU738030B2 (en) 2001-09-06
HUP0000886A2 (hu) 2000-09-28
CY2480B1 (en) 2005-06-03
CA2277791C (en) 2008-11-18
PE58999A1 (es) 1999-06-25
NO993919D0 (no) 1999-08-13
PL334959A1 (en) 2000-03-27
CZ298840B6 (cs) 2008-02-20
NO327486B1 (no) 2009-07-13
ATE239481T1 (de) 2003-05-15
UY24888A1 (es) 2000-12-29
CN1626093A (zh) 2005-06-15
JP2006077029A (ja) 2006-03-23
EP0966287A1 (en) 1999-12-29
CO4920215A1 (es) 2000-05-29
ID22348A (id) 1999-09-30
ES2199422T3 (es) 2004-02-16
NZ336946A (en) 2001-02-23
CZ287999A3 (cs) 1999-11-17
TW529957B (en) 2003-05-01
PL193332B1 (pl) 2007-02-28
CN1247471A (zh) 2000-03-15
JP2010132694A (ja) 2010-06-17
US20080014269A1 (en) 2008-01-17
BR9807368A (pt) 2000-03-14
EP0966287B1 (en) 2003-05-07
US20070036863A1 (en) 2007-02-15
SK109899A3 (en) 2000-03-13
AU6622298A (en) 1998-09-08
DE69814367D1 (de) 2003-06-12
ZA981205B (en) 1998-08-14
RU2201218C2 (ru) 2003-03-27
JP2000511935A (ja) 2000-09-12
WO1998035681A1 (en) 1998-08-20
HU227807B1 (en) 2012-03-28
SK284503B6 (sk) 2005-05-05
HUP0000886A3 (en) 2002-10-28
KR20090037873A (ko) 2009-04-16
NO993919L (no) 1999-08-13
TR199901804T2 (xx) 1999-09-21
HK1024423A1 (en) 2000-10-13
CN1170542C (zh) 2004-10-13
PT966287E (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
MY117582A (en) Oxacarbazepine film-coated tablets
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
AU689036B2 (en) Pharmaceutical composition containing substance inhibiting HSP47 production
AU5861499A (en) Agitation-independent pharmaceutical multiple unit retard preparations and method for the production thereof
HUP9900028A3 (en) Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
NZ512683A (en) Taste-masked pharmaceutical particles that are suitable for making chewable tablets
NZ213245A (en) Controlled-release coated pharmaceutical tablets
HUP9603112A2 (en) New pharmaceutical formulation and process for its production
CA2307018A1 (en) Osmotic medicament releasing system
CA2182939A1 (en) A rapidly disintegrating medicinal form of tramadol or a tramadol salt
AU1671799A (en) Medicament preparation in the form of a tablet or pellet for acid-labile active substances
CA2162470A1 (en) Tablet with Improved Bioavailability Containing Dichloromethylenediphosphonic Acid as the Active Substance
HUP0004407A1 (hu) Eprosartant tartalmazó, azonnali és módosított hatóanyag-felszabadítású, orális adagolású készítmények és előállítási eljárásaik
AU3970793A (en) Methods of manufacturing high dosage glutathione, the tablets and capsules produced thereby
GR1002034B (en) Process for the preparation of dry processed particles dry processed particles thus obtained and pharmaceutical compositions containing such particles.
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
PL327584A1 (en) Active substance quckly releasing tablet containing tolphenamica acid or its pharmaceutically acceptable salt
HRP920575B1 (en) Solid oral administration forms containing ifosfamide as an active agent and a process for the production of the same
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
IL117078A (en) Substituted benzenesulfonylureas and-thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and pharmaceutical preparations containing them
AU6738496A (en) Process for preparing solid dosage forms of very low-dose drugs
AU4560096A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and medicaments containing them
AU7705396A (en) Quinoxaline compounds, pharmaceutical preparations containing them and a process for the preparation thereof
AUPM814994A0 (en) Codeine-containing formulations
HUP9801846A3 (en) 17-difluoromethylene-oestratrienes, use thereof medicaments containing them and process for production of compounds